pany's initial products are intended to
reduce the risks, trauma and costs associated with current open, arrested
heart surgical options. The company's present development and clinical
efforts are focused on mitral valve repair. For more information about
Evalve, Inc., visit
http://www.evalveinc.com.
MitraClip and Evalve are registered trademarks of Evalve, Inc.
'/>"/>SOURCE Evalve, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related medicine technology :1.
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs2.
International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis3.
New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility4.
MediGene Announces Cancer-Fighting Virus Shows Promise in Early
Clinical Trial5.
Study Shows Ixabepilone Demonstrated Clear Activity in Patients
with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,
and Capecitabine6.
Ceragenix Compound Shows Promise for Treating Lethal Cystic
Fibrosis Infections7.
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types8.
CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and
Pain, but Not CRP9.
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes
Using Self-Adjusted Dosing Starting With Once-Daily Insulin
Treatment Levemir10.
First Phase II Short-Term Study on Dapagliflozin Shows Results on
Safety, Tolerability and Glycemic Markers in Subjects With Type 2
Diabetes11.
New Poll Shows Men, Women Incorrectly Blame Symptoms of Low
Testosterone on Normal Aging